📰 Registration Document News
Page 83 - Registration Document News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Registration Document. Real-time updates on events, politics, business and more.
January 25, 2023
SOITEC REPORTS FY'23 THIRD QUARTER REVENUE Q3'23 revenue reached €274m, up 32% on a reported basis and up 25% at constant exchange rates and perimeterSharp growth achieved in both Automotive & Industrial
January 25, 2023
Highlights & business update of the 2nd half of 2022 Progress on green and renewable hydrogen production projects Industrial and technological agreements to secure access to strategic equipment Structuring
January 24, 2023
Sales of Sibnayal® reached 1.4 million euros, a significant increase of 40% over one year Significant growth acceleration in H2 2022 Regulatory News: Advicenne (Euronext: ADVIC), a specialty
January 24, 2023
Regulatory News: Mauna Kea Technologies (Euronext: MKEA,) (Paris:MKEA) (OTCQX:MKEAY) inventor of Cellvizio®, the multi-disciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE)
January 20, 2023
Investigational Onivyde (irinotecan liposome injection) in the NALIRIFOX treatment regimen demonstrated statistically significant improvements in overall survival and progression-free survival compared
January 17, 2023
Contacts Media Contact Investor Relations Amsterdam +31 20 721 4133 Brussels +32 2 620 15 50 +33 1 70 48 24 27 Dublin +33 1 70 48 24 45 Lisbon +351 210 600 614 Milan +39 02 72 42 62 12
January 12, 2023
Results were published in Respirology and provide further evidence supporting Cellvizio as a key complementary technology to robotic-assisted bronchoscopy, potentially impacting patient management
January 9, 2023
Transaction focused on Bylvay (odevixibat), the first-approved treatment in progressive familial intrahepatic cholestasis in U.S. and E.U., with potential in other rare diseases Acquisition
January 9, 2023
Full Text View - ClinicalTrials.gov Hopkins P J Pediatr. 2017;187:253-257. doi: 10.1016/j.jpeds.2017.05.006. Epub 2017 Jun 1. ... | January 9, 2023
January 9, 2023
Ipsen and Albireo announced that they have entered into a definitive merger agreement under which Ipsen will acquire Albireo, a leading innovator in bile-acid modulators to treat pediatric and adult cholestatic liver diseases.